For US Healthcare Professionals Only
For US Healthcare Professionals Only
At IncyteCARES, our mission is to help eligible patients access their prescribed Incyte medication and to offer information and resources that provide extra support during treatment. Our team is available to patients and their caregivers by phone every weekday.
Review additional terms and conditions
for copay/coinsurance*
You may enroll your eligible patients online.
IncyteCARES Online
Enrollment Form
Connect with IncyteCARES today!
Visit IncyteCARES.com or call 1-855-452-52341-855-452-5234, Monday through Friday, 8 AM to 8 PM ET.
Visit IncyteCARES.com
Information about independent organizations‡ that may be able to assist with:
*Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE, or any state medical or pharmaceutical assistance program. A monthly and yearly maximum benefit applies. Limit one 30-day supply per 30 days. Valid prescription for Jakafi® (ruxolitinib) for an FDA-approved indication or compendia-recognized use is required. Please see full criteria for eligibility or call IncyteCARES for Jakafi at 1-855-452-52341-855-452-5234. Update effective as of March 1, 2023.
†Terms and conditions apply. Terms of this program may change at any time.
‡Some organizations may receive donations from Incyte Corporation.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.